Author

Mert Erciyestepe

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Thymic carcinoma (TC) is a rare and aggressive malignancy with limited evidence guiding second-line treatment after prior systemic therapy. We evaluated real-world outcomes of second-line systemic therapy in a multicenter cohort. Adults with unresectable, recurrent, or metastatic TC who received second-lin...

Fatih Kuş, Fatih Atalah, Gökhan Şahin et al. · BMC Cancer · 0 citations

Open access 2026

Baseline LDL-to-Monocyte Ratio as a Prognostic Biomarker in Advanced Inoperable Ovarian Cancer

Objective: Studies have shown that higher levels of peripheral monocytes are associated with poorer survival rates in various advanced cancers, suggesting that they could serve as markers of an immune response that promotes tumor growth. Additionally, modified lipoproteins, particularly oxidized LDL, can directly activ...

Mert Erciyestepe, Ayşenur Burcu Emetli, İldeniz Bilgiçler Uçar et al. · Comprehensive Medicine · 0 citations

Review Open access Sep 2026

The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience

The role of ovarian function suppression (OFS) in premenopausal patients with hormone receptor (HR)-positive, HER2-positive breast cancer remains unclear in the era of anti-HER2 therapy. This study evaluated the effect of adding OFS to adjuvant endocrine therapy on outcomes in premenopausal patients receiving neoadjuva...

Okan Aydın, Hale Gülçin Yıldırım Doğan, Şermin Dinç Sonuşen et al. · BMC Cancer · 0 citations